Where does Rottapharm Biotech S.R.L. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Rottapharm Biotech S.R.L. ranks #23,317 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Rottapharm Biotech S.R.L. hold?

Rottapharm Biotech S.R.L. holds 12 US utility patents granted between 2015 and 2025, spanning 7 technology areas.

What is Rottapharm Biotech S.R.L.'s Innovation Score?

Rottapharm Biotech S.R.L. has an Innovation Score of 38.6 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Rottapharm Biotech S.R.L. focus on?

Rottapharm Biotech S.R.L.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 10 patents, ranking #1,884 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Rottapharm Biotech S.R.L.'s patent grant rate increasing or decreasing?

Rottapharm Biotech S.R.L.'s recent grant velocity is -78% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Rottapharm Biotech S.R.L.'s patents?

Rottapharm Biotech S.R.L.'s patents average 11.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Rottapharm Biotech S.R.L. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Rottapharm Biotech S.R.L.

USPTO PatentsView assignee record - 12 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Rottapharm ranks #23,317 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 7 technology areas.

#23,317
of 49,997 US assignees by volume: Top 40%
by Innovation Score (38.6/100): 11.8
avg claims per patent: -78%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23317 · Foreign Corporation #23,317 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 12 grants
MID-PACK #23,317/49,997
PHOTO-FINISH Rodenhouse
CPC-NARROW A61P · 7 areas
INNOV-THIN 38.6/100
CLAIMS-PAR 11.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -78% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Rodenhouse, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Rottapharm’s 38.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (23%) Velocity 13.3 pts (34%) Breadth 9.4 pts (24%) Claim depth 7.1 pts (18%)

Qualcomm Incorporated · highest

85
IronRidge · near

39
Mati Therapeutics · near

39
Nexrf · near

39
Rottapharm Biotech… · this assignee

39
Soin Neuroscience · near

39
3D Lighting… · lowest

7

What this shows Rottapharm's Innovation Score is 38.6/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Rottapharm?

Each dot is one of Rottapharm’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Rottapharm’s own 11.8 claims/patent is ABOVE the 7.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Rottapharm vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Rottapharm's grants concentrate

Rottapharm Biotech S.R.L. is a focused PatentsView assignee: 7 CPC subclasses with 83.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2017. By volume, Rottapharm sits between Rodenhouse, Inc. and S-Tec Corporation.

Rottapharm's three-year grant acceleration

Rottapharm Biotech S.R.L. shows 2 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Rodenhouse

12
Roger Webb Associ…

12
Roll Recovery

12
Rolling Razor

12
Rounderbum

12
Route4me

12
S+S Industries Te…

12
S-tec

12
Rottapharm Biotec… ◀

12

What this shows Rottapharm holds 12 patents at rank #23,309, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Rottapharm

By rank, the assignees closest to #23,309 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Rottapharm's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Rottapharm, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Rottapharm ranks #1,884 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Soin Neuroscience, LLC 39 Nexrf Corp. 39 Mati Therapeutics, Inc. 39 IronRidge, Inc. 39

Rottapharm's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Rottapharm Biotech S.R.L. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	41.7%
2016	2	16.7%
2017	1	8.3%
2018	1	8.3%
2023	2	16.7%
2025partial year	1	8.3%

Which technologies does Rottapharm Biotech S.R.L. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

C07D - Heterocyclic Compounds 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07K - Peptides 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Rottapharm Biotech S.R.L.'s patent record in context - here's where to go next.

Rottapharm Biotech S.R.L.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 83.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #23,317 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Rottapharm Biotech S.R.L. against Rodenhouse, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.